SGRY
Surgery Partners Inc
Surgery Partners Inc historical holders
total: 2
Oaktree Capital Management Surgery Partners Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
Howard Marks has been an institutional investor in Surgery Partners Inc (SGRY) since 2026 Q2. According to 2026 Q2 report, Howard Marks holds 862,588 shares with a market value of roughly $14.49M representing 0.27% of their equity portfolio. The fund/company first acquired SGRY in 2026 Q2, initially purchasing 862,588 shares.
Does Howard Marks still hold SGRY?
Yes, Howard Marks continues to hold Surgery Partners Inc (SGRY). According to their 2026 Q2 report, they maintain a position of 862,588 shares valued at approximately $14.49M, representing 0.27% of their equity portfolio.
When did Howard Marks first invest in SGRY?
Howard Marks first invested in Surgery Partners Inc (SGRY) in 2026 Q2 at the reported quarter-end price of $16.80 per share, acquiring 862,588 shares in their initial purchase.
What is Howard Marks's average cost basis for SGRY?
Based on historical transaction data, Howard Marks's estimated cost basis for Surgery Partners Inc (SGRY) is approximately $16.80 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $16.80
SGRY transactions history by Oaktree Capital Management
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.27%
|
862,588
|
$16.80
|
$14,491,478
|
new
|
+0.27%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.